Medical management of pulmonary disease caused by Mycobacterium avium complex (Q34949913)

5 August 2017

1 reference

title

Medical management of pulmonary disease caused by Mycobacterium avium complex (English)

1 reference

Mycobacterium avium avium

5 August 2017

1 reference

1 reference

Michael D Iseman

1

1 reference

5 August 2017

publication date

1 September 2002

1 reference

Clinics in Chest Medicine

5 August 2017

published in

1 reference

5 August 2017

volume

23

1 reference

5 August 2017

issue

3

1 reference

5 August 2017

page(s)

633-41, vii

1 reference

Diagnosis and treatment of disease caused by nontuberculous mycobacteria

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Treatment of Disease Due to Mycobacterium intracellulare

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Susceptibility testing of Mycobacterium avium complex isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Evidence that antituberculosis drugs are really effective in the treatment of pulmonary infection caused by Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Choice of antimicrobial agents for M. avium disease based on quantitative tests of drug susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Clarithromycin against Mycobacterium avium complex infections

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex. Bactericidal synergistic, and bacteriostatic additive or synergistic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. MAC Study Group of the Canadian HIV Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Rifamycin-induced lupus syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

In vitro synergistic activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin against Mycobacterium avium-intracellulare complex

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Activity of moxifloxacin against mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Activity of rifabutin alone and in combination with clofazimine, kanamycin and ethambutol against Mycobacterium intracellulare infections in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Thiacetazone: in vitro activity against mycobacterium avium and m. tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

In vitro and in vivo synergistic effect of isoniazid with streptomycin and clofazimine against Mycobacterium avium complex (MAC)

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

Surgical management of resistant mycobacterial tuberculosis and other mycobacterial pulmonary infections

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2802%2900023-0

7 January 2021

10.1016/S0272-5231(02)00023-0

Identifiers

DOI

1 reference

5 August 2017

1 reference